Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Rachel A. Kudgus
A Study of Axitinib, a VEGF Receptor Tyrosine Kinase Inhibitor, in Children and Adolescents With Recurrent or Refractory Solid Tumors: A Children’s Oncology Group Phase 1 and Pilot Consortium Trial (ADVL1315)
Cancer
Cancer Research
Oncology
Related publications
A Phase I Trial of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL0916)
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Pediatric Phase 1 Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors ADVL1115: A Children's Oncology Group Phase 1 Consortium Report
Clinical Cancer Research
Cancer Research
Oncology
Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
A Phase I Trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-Vegfr Inhibitor, in Children With Recurrent or Refractory Primary CNS Tumors
Child's Nervous System
Medicine
Child Health
Neurology
Pediatrics
Perinatology
A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience
Clinical Cancer Research
Cancer Research
Oncology
Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
Urology
Urology
Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Receptor Tyrosine Kinase (RTK); VEGF-A
Science-Business eXchange
